News Ipsen

Equities

IPN

FR0010259150

Real-time Euronext Paris Other stock markets 09:36:00 2024-04-18 am EDT			5-day change	1st Jan Change
105.7 ^EUR	-0.66%		-3.38%	-2.04%

Apr. 15	Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	CF
Apr. 02	Ipsen: worldwide licensing agreement with Sutro Biopharma	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ipsen publishes its 2023 Universal Registration Document	Apr. 17	GL
Ipsen publishes its 2023 Universal Registration Document	Apr. 17	AQ
Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	Apr. 15	CF
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen	Apr. 03	AQ
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors	Apr. 02	GL
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating	Feb. 16	MT
IPSEN : Deutsche Bank cuts its target	Feb. 16	CF
Ipsen S.A. publishes its 2023 Consolidated Financial Statements	Feb. 15	GL
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 14	AQ
IPSEN : UBS reiterates its buy recommendation	Feb. 14	CF
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Ipsen: new indication approved in pancreatic cancer	Feb. 14	CF
US FDA OKs Ipsen's Metastatic Pancreatic Adenocarcinoma Treatment Regimen in Adults	Feb. 13	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA	Feb. 13	GL
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	Feb. 13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

IPSEN : Ipsen’s underlying fundamentals remain promising

March 13, 2024 at 11:50 am EDT